J Korean Med Sci.
2019 May;34(17):e133. 10.3346/jkms.2019.34.e133.
Prognostic Effect of Guideline-Directed Therapy Is More Noticeable Early in the Course of Heart Failure
- Ahn MS
- Yoo BS
- Yoon J
- Lee SH
- Kim JY
- Ahn SG
- Youn YJ
- Lee JW
- Son JW
- Kim HS
- Kang DR
- Lee SE
- Cho HJ
- Lee HY
- Jeon ES
- Kang SM
- Choi DJ
- Cho MC
- Affiliations
-
- 1Division of Cardiology, Department of Internal Medicine, Wonju Severance Christian Hospital, Yonsei University, Wonju College of Medicine, Wonju, Korea. yubs@yonsei.ac.kr
- 2Center of Biomedical Data Science, Yonsei University, Wonju College of Medicine, Wonju, Korea.
- 3Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
- 4Department of Internal Medicine, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul, Korea.
- 5Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
- 6Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
- 7Department of Internal Medicine, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Korea.
- KMID: 2444746
- DOI: http://doi.org/10.3346/jkms.2019.34.e133
Abstract
- BACKGROUND
There have been few studies to evaluate the prognostic implications of guideline-directed therapy according to the temporal course of heart failure. This study assessed the relationship between adherence to guideline-directed therapy at discharge and 60-day clinical outcomes in de novo acute heart failure (AHF) and acute decompensated chronic heart failure (ADCHF) separately.
METHODS
Among 5,625 AHF patients who were recruited from a multicenter cohort registry of Korean Acute Heart Failure, 2,769 patients with reduced ejection fraction were analyzed. Guideline-directed therapies were defined as the use of angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor II blocker (ARB), β-blocker, and mineralocorticoid receptor antagonist.
RESULTS
In de novo AHF, ACEI or ARB reduced re-hospitalization (hazard ratio [HR], 0.57; 95% confidence interval [CI], 0.34-0.95), mortality (HR, 0.41; 95% CI, 0.24-0.69) and composite endpoint (HR, 0.52; 95% CI, 0.36-0.77) rates. Beta-blockers reduced re-hospitalization (HR, 0.62; 95% CI, 0.41-0.95) and composite endpoint (HR, 0.65; 95% CI, 0.47-0.90) rates. In ADCHF, adherence to ACEI or ARB was associated with only mortality and β-blockers with composite endpoint.
CONCLUSION
The prognostic implications of adherence to guideline-directed therapy at discharge were more pronounced in de novo heart failure. We recommend that guideline-directed therapy be started as early as possible in the course of heart failure with reduced ejection fraction.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Paradigm Shifts of Heart Failure Therapy: Do We Need Another Paradigm?
- Optimization of guideline-directed medical treatment for heart failure patients with reduced ejection fraction
- Update of Sepsis: Recent Evidences about Early Goal Directed Therapy
- Angiotensin Receptor Neprilysin Inhibitors in HFrEF: Is This the First Disease Modifying Therapy Drug Class Leading to a Substantial Reduction in Diuretic Need?
- Frailty, Sarcopenia, Cachexia, and Malnutrition in Heart Failure
